TaiwanJ Pharmaceuticals Co., Ltd is a specialty pharmaceutical company dedicated to the development and commercialization of small molecules for unmet medical needs such as chronic organ inflammation of metabolic, autoimmune and infectious etiologies. In addition, novel steroid-sparing therapies for allergy/asthma are being pursued.
The Company's initial drug development strategy is to reduce time-to-market, lower risks of clinical trial, and minimize development costs by re-profiling approved drugs such as JKB-122 and JKB-121, via 505(b)(2) regulatory pathway initially. In addition, the company is developing a rich pipeline of novel chemical entities (NCEs) for therapy to address chronic liver diseases and allery/asthma. Specific diseases targeted include liver inflammation/liver fibrosis, NASH, NAFLD, autoimmune diseases autoimmune hepatitis), asthma and atopic dermatitis.

TLR4 antagonists ameliorate chronic and acute tissue inflammation through deactivating macrophages and modulating proinflammatory cytokines. The lead TLR4 antagonists are JKB-122 and JKB-121, which are currently under four clinical trial evaluations for treating HCV/HBV-associated liver inflammation/fibrosis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), and autoimmune hepatitis (AIH), an orphan disease. Other approaches include autotaxin inhibitors (ATXi) and acetyl Co A carboxylase inhibitors (ACCi) for the treatment of NAFLD and NASH.

Inhibition of IL-4 and IL-13 through Th2-based mechanism will form the basis of novel therpy for asthma and atopic dermatitis. The advantages of small molecules would include safety (vs steroids) and cost-effectiveness (vs biologics).

TaiwanJ seeks product development collaborations and strategic alliances to develop its pipeline of products into the market.